| 淡江大學 |
2012-07-06 |
First-fit chromatic numbers of d-degenerate graphs
|
Chang, Gerard Jennhwa;Hsu, Hsiang-Chun |
| 國立臺灣大學 |
2012 |
First-generation college students' information seeking: Their personality traits and source use behavior in coursework-related context
|
TIEN-I TSAI; Tsai, T.-I. and Kim, K.-S. |
| 國立高雄師範大學 |
1998 |
First-grade children’s use of analogy in word reading
|
C. C. Wang;J. S. Gaffney |
| 國家衛生研究院 |
2021-08-12 |
First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients
|
Huang, JF;Dai, CY;Huang, CF;Tsai, PC;Yeh, ML;Hsu, PY;Huang, SF;Bair, MJ;Hou, NJ;Huang, CI;Liang, PC;Lin, YH;Wang, CW;Hsieh, MY;Chen, SC;Lin, ZY;Yu, ML;Chuang, WL |
| 國家衛生研究院 |
2024-01-29 |
First-in-class dual EZH2-HSP90 inhibitor eliciting striking antiglioblastoma activity in vitro and in vivo
|
Sharma, S;Wang, SA;Yang, WB;Lin, HY;Lai, MJ;Chen, HC;Kao, TY;Hsu, FL;Nepali, K;Hsu, TI;Liou, JP |
| 臺大學術典藏 |
2021-07-21T23:21:30Z |
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma
|
Italiano, Antoine; Cassier, Philippe A.; Chia-Chi Lin; Alanko, Tuomo; Peltola, Katriina J.; Gazzah, Anas; Shiah, Her Shyong; Calvo, Emiliano; Cervantes, Andrés; Roda, Desamparados; Tosi, Diego; Gao, Bo; Millward, Michael; Warburton, Lydia; Tanner, Minna; Englert, Stefan; Lambert, Stacie; Parikh, Apurvasena; Afar, Daniel E.; Vosganian, Gregory; Moreno, Victor |
| 臺大學術典藏 |
2022-09-15T01:08:44Z |
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma
|
Italiano A.; Cassier P.A.; Chia-Chi Lin; Alanko T.; Peltola K.J.; Gazzah A.; Shiah H.-S.; Calvo E.; Cervantes A.; Roda D.; Tosi D.; Gao B.; Millward M.; Warburton L.; Tanner M.; Englert S.; Lambert S.; Parikh A.; Afar D.E.; Vosganian G.; Moreno V. |
| 國立臺灣大學 |
2015 |
First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M.
|
Tan, Daniel Shao-Weng; Seto, Takashi; Leighl, Natasha B.; Riely, Gregory J.; Sequist, Lecia V.; Felip, Enriqueta; Wolf, Juergen; Yang, James Chih-Hsin; Matushansky, Igor; Yu, Xiaolu; Schmitz, Shu-Fang Hsu; Cui, Xiaoming; Kim, Dong-Wan; 楊志新 |
| 臺大學術典藏 |
2021-08-11T03:46:35Z |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. |
| 臺大學術典藏 |
2022-06-10T06:10:56Z |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. |
| 國立成功大學 |
2019 |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim, R.D.;Sarker, D.;Meyer, T.;Yau, T.;Macarulla, T.;Park, J.-W.;Choo, S.P.;Hollebecque, A.;Sung, M.W.;Lim, H.-Y.;Mazzaferro, V.;Trojan, J.;Zhu, A.X.;Yoon, J.-H.;Sharma, Sharma S.;Lin, Z.-Z.;Chan, S.L.;Faivre, S.;Feun, L.G.;Yen, C.-J.;Dufour, J.-F.;Palmer, D.H.;Llovet, J.M.;Manoogian, Manoogian M.;Tugnait, M.;Stransky, N.;Hagel, M.;Kohl, N.E.;Lengauer, C.;Sherwin, C.A.;Schmidt-Kittler, O.;Hoeflich, K.P.;Shi, H.;Wolf, B.B.;Kang, Y.-K. |
| 中山醫學大學 |
2020 |
First-in-Human study of JNJ-55920839 in healthy volunteers and patients with systemic lupus erythematosus: a randomised placebo-controlled phase 1 trial
|
Jordan, J; Benson, J; Chatham, WW; Furie, RA; Stohl, W; Wei, JCC; Marciniak, S; Yao, ZL; Srivastava, B; Schreiter, J; Cesaroni, M; Orillion, A; Seridi, L; Chevrier, M |
| 臺大學術典藏 |
2020-05-26T09:26:20Z |
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials
|
Schuler M;Paz-Ares L;Sequist L.V;Hirsh V;Lee K.H;Wu Y.-L;Lu S;Zhou C;Feng J;Ellis S.H;Samuelsen C.H;Tang W;M?rten A;Ehrnrooth E;Park K;Chih-Hsin Yang; Schuler M; Paz-Ares L; Sequist L.V; Hirsh V; Lee K.H; Wu Y.-L; Lu S; Zhou C; Feng J; Ellis S.H; Samuelsen C.H; Tang W; Märten A; Ehrnrooth E; Park K; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:22Z |
First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ?�real-world??clinical setting
|
Park K;Wan-Teck Lim D;Okamoto I;Chih-Hsin Yang; Park K; Wan-Teck Lim D; Okamoto I; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:48Z |
First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases
|
Chih-Hsin Yang;Zazulina V;Massey D;Sequist L.V;Popat S;Mok T;Yamamoto N;O'Byrne K;Hirsh V;Wu Y.-L;Schuler M; Schuler M; Wu Y.-L; Hirsh V; O'Byrne K; Yamamoto N; Mok T; Popat S; Sequist L.V; Massey D; Zazulina V; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:20Z |
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
|
Schuler M;Tan E.-H;O??Byrne K;Zhang L;Boyer M;Mok T;Hirsh V;Chih-Hsin Yang;Lee K.H;Lu S;Shi Y;Kim S.-W;Laskin J;Kim D.-W;Arvis C.D;K?lbeck K;Massey D;M?rten A;Paz-Ares L;Park K.; Schuler M; Tan E.-H; O?�Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Massey D; Märten A; Paz-Ares L; Park K. |
| 臺大學術典藏 |
2022-05-10T08:09:28Z |
First-line anaplastic lymphoma kinase (Alk) inhibitors for alk-positive lung cancer in asian populations: Systematic review and network meta-analysis
|
Wu K.-L.; Chen H.-L.; Tsai Y.-M.; Lee T.-H.; Chang H.-M.; Tsai Y.-C.; Chuang C.-H.; Chang Y.-C.; YU-KANG TU; Yang C.-J.; Hung J.-Y.; Chong I.-W. |
| 國家衛生研究院 |
2017-10 |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo, SH;Yeh, KH;Wu, MS;Lin, CW;Wei, MF;Liou, JM;Wang, HP;Chen, LT;Cheng, AL |
| 臺大學術典藏 |
2018-09-10T18:04:32Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo, S.-H. and Yeh, K.-H. and Wu, M.-S. and Lin, C.-W. and Wei, M.-F. and Liou, J.-M. and Wang, H.-P. and Chen, L.-T. and Cheng, A.-L.; JYH-MING LIOU; CHUNG-WU LIN; MING-SHIANG WU; ANN-LII CHENG |
| 臺大學術典藏 |
2020-03-03T03:36:41Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo S.-H.;Yeh K.-H.;Wu M.-S.;Chung-Wu Lin;Wei M.-F.;Liou J.-M.;Wang H.-P.;Chen L.-T.;Cheng A.-L.; Kuo S.-H.; Yeh K.-H.; Wu M.-S.; CHUNG-WU LIN; Wei M.-F.; Liou J.-M.; Wang H.-P.; Chen L.-T.; Cheng A.-L. |
| 臺大學術典藏 |
2020-11-02T02:04:20Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Cheng A.-L.; Chen L.-T.; Wang H.-P.; Liou J.-M.; Wei M.-F.; Lin C.-W.; MING-SHIANG WU; Yeh K.-H.; Kuo S.-H. |
| 臺大學術典藏 |
2021-02-23T08:26:17Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Sung-Hsin Kuo;Yeh K.-H.;Wu M.-S.;Lin C.-W.;Wei M.-F.;Liou J.-M.;Wang H.-P.;Chen L.-T.;Cheng A.-L.; SUNG-HSIN KUO; Yeh K.-H.; Wu M.-S.; Lin C.-W.; Wei M.-F.; Liou J.-M.; Wang H.-P.; Chen L.-T.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-15T03:46:33Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo S.-H.; Yeh K.-H.; Wu M.-S.; Lin C.-W.; Wei M.-F.; Liou J.-M.; HSIU-PO WANG; Chen L.-T.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:22Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo S.-H.;Kun-Huei Yeh;Wu M.-S.;Lin C.-W.;Wei M.-F.;Liou J.-M.;Wang H.-P.;Chen L.-T.;Cheng A.-L.; Kuo S.-H.; KUN-HUEI YEH; Wu M.-S.; Lin C.-W.; Wei M.-F.; Liou J.-M.; Wang H.-P.; Chen L.-T.; Cheng A.-L. |
| 國立成功大學 |
2017 |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo, S.-H.;Yeh, K.-H.;Wu, M.-S.;Lin, C.-W.;Wei, M.-F.;Liou, J.-M.;Wang, H.-P.;Chen, L.-T.;Cheng, A.-L. |
